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The goals of the initial management of ST-segment elevation myocardial infarction include swift restoration of flow within the occluded coronary artery, prevention of early reinfarction, and avoidance of complications of reperfusion therapy. 1,2 The selection of the reperfusion strategy, either the preferred percutaneous coronary intervention (PCI) or fibrinolysis, is usually driven by institutional access to primary PCI. Thus, the decision that clinicians most commonly grapple with at the time of the patient's presentation is the selection of adjunctive anticoagulant and antiplatelet therapy. In this issue of the Journal, Stone and colleagues report on a large, randomized trial that tested an anticoagulant agent in primary PCI. 3 When performed rapidly by an experienced team, primary PCI restores flow in the culprit artery in more than 95% of patients and, as compared with fibrinolysis, reduces the risk of reinfarction by more than 50%, but with a higher risk of extracranial bleeding. 4 Thus, the goals of antithrombotic therapy for primary PCI differ from those for fibrinolysis, which fails to restore coronary flow or culminates in early reocclusion in approximately 20% of patients. 5 Antithrombotic therapy in primary PCI is focused on minimizing the thrombotic complications of mechanical intervention. Only modest absolute reductions in early spontaneous reinfarction are possible because the absolute risk is 3% or less. 4 Although antithrombotic therapy facilitates improved flow before angiography, the effect appears to be small if the pretreatment is brief.
Current guidelines for ancillary antithrombotic therapy recommend that patients who are undergoing primary PCI receive aspirin and a loading dose of clopidogrel, generally 600 mg, before or at the time of PCI. 1,2,6 On the basis of expert consensus, unfractionated heparin is recommended in patients undergoing primary PCI (class I [treatment should be administered], according to the American College of Cardiology/American Heart Association guidelines). A large, randomized trial of the pentasaccharide factor Xa inhibitor fondaparinux in patients with ST-segment elevation myocardial infarction, including 3789 patients who were undergoing primary PCI, revealed a possible hazard related to catheter thrombosis. 9 Therefore, fondaparinux is not recommended as the sole anticoagulant for primary PCI. 2,6 Evaluation of low-molecular-weight heparins in patients undergoing primary PCI has not been sufficient to allow recommendation of the use of these agents for this indication.
The direct thrombin inhibitor bivalirudin is a short-acting anticoagulant that, when administered for a short interval during PCI, has been found to reduce bleeding as compared with heparin plus a glycoprotein IIb/IIIa inhibitor. 10 The trial of bivalirudin in primary PCI reported by Stone et al. addressed an important and untested hypothesis. Strengths of the trial include a large sample, a well-defined population that is relevant to clinical practice, and a comparison of bivalirudin with a treatment that is representative of contemporary practice. The primary result, that bivalirudin alone reduced a composite end point of major bleeding and major cardiovascular events by 24% at 30 days owing to a 40% reduction in the primary bleeding end point, is compelling with respect to the potential for bivalirudin as antithrombotic therapy in this setting.
There are several aspects of the trial design and results that merit careful consideration, since they affect the strength of the findings and the potential application in clinical practice and reveal trade-offs between the efficacy of antithrombotic therapy and the risk of bleeding. First, the limitation of an open-label design requires emphasis, since this study design weakens the conclusiveness of any analysis of end points, such as bleeding and ischemic events, for which there may be bias in reporting by the local investigator on the basis of treatment. However, the consistency of the reduction in bleeding across multiple definitions and trials bolsters this finding as a qualitative conclusion. 10 Second, the effect of the administration of another antithrombin agent (unfractionated heparin) in approximately 65% of the patients shortly before PCI warrants consideration. Bivalirudin was tested as monotherapy in only 615 patients. In this group, major cardiovascular events occurred in 7.2% of the patients, as compared with 5.2% of the patients who received heparin plus a glycoprotein IIb/IIIa inhibitor (relative risk, 1.39; 95% CI, 0.85 to 2.28), with interaction testing suggesting heterogeneity (P<0.1). Even with cautious interpretation of this interaction testing, the administration of unfractionated heparin before enrollment to the majority of patients in the study mitigates the strength of the results with respect to clinical practice in which bivalirudin might be used as monotherapy. Third, the duration of treatment before PCI was not reported 3 and is relevant to the effect of glycoprotein IIb/IIIa antagonists in STsegment elevation myocardial infarction. 11 It is not clear whether the findings of this study apply when a period of treatment before PCI is necessary, such as during the common practice of transferring patients to a different hospital for primary PCI.
The early 1% absolute excess in the number of cases of stent thrombosis in the bivalirudin group, as compared with the group that received heparin plus a glycoprotein IIb/IIIa inhibitor (P<0.001), should be acknowledged as an important finding and as a signal that bivalirudin has less antithrombotic efficacy than heparin plus a glycoprotein IIb/IIIa inhibitor early after PCI when the treatment regimens are pharmacologically active. Moreover, the finding is concordant with the pattern of a higher early incidence of cardiovascular events and death from cardiac causes that is evident from the Kaplan−Meier plots. The number of cases of early stent thrombosis was increased despite the administration of a loading dose of 600 mg of clopidogrel in more than 60% of the patients. This early hazard did not increase the rate of reinfarction or death at 30 days in this trial. However, periprocedural myocardial infarction will be obscured by increases in biomarkers that are due to the presenting ST-segment elevation myocardial infarction. Moreover, stent thrombosis may have more serious consequences when it occurs more broadly in the community, where there may be a more limited capacity to perform immediate repeat PCI. This finding may stimulate the investigation of alternatives to address the risk of early stent thombosis, such as treatment with newer potent and rapidly acting oral antiplatelet agents. 12 The robustness of the intriguing finding that bivalirudin alone may lower mortality must be interpreted as a secondary finding of a single trial, with broad confidence limits (95% CI, 0.44 to 1.00). The authors suggest the hypothesis that reduced bleeding was a causal factor in the observed reduction in mortality. 3 This possibility is supported by an analogous finding with fondaparinux. 13 However, evidence of an independent relationship between bleeding and mortality is mixed, and there is a very high likelihood of residual confounding by clinical characteristics associated with poor survival. 14,15 An observational study of bleeding in 40,087 patients with myocardial infarction showed that bleeding was primarily a marker rather than a mediator of the risk of death. 15 In addition, it is evident from the study by Stone et al. that bleeding-related deaths (included as deaths from noncardiac causes) did not account for a difference in survival. The finding of a possible decrease in deaths with bivalirudin alone is interesting and supports the continued pursuit of an optimal balance in the trade-off between bleeding and thrombotic complications, as well as a clearer understanding of whether our clinical responses to bleeding may be detrimental.
Stone and colleagues have substantially increased the experience with bivalirudin in a new setting. Although their study is a single open-label trial with limitations and observations that call for additional investigation, their findings indicate that bivalirudin warrants consideration among the alternatives for ancillary antithrombotic therapy in patients undergoing primary PCI.
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